Immuron LimitedASX: IMC

Clinical Trial Update

· Issued by Immuron Limited

Filed with ASX · · 5 pages · English

Summary by 6ix AI

Additionally, topline data from the Travelan® study has been delayed due to a government shutdown, now expected at the end of November. The results from this study will influence Immuron's dosing strategy for an upcoming meeting with the FDA regarding Travelan®.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immuron Limited on 6ix

Story so far

Earlier from Immuron

Later from Immuron

All Immuron news releases